港股異動 | 威高股份(1066.HK)大漲13%破頂 獲機構持續唱好
格隆匯7月22日丨威高股份(1066.HK)漲13.04%,報21.5港元再創新高,暫成交4.2億港元,最新總市值972.3億港元。公司股價自4月以來累計上漲超120%續創新高。近期持續獲機構唱好。富瑞恢復威高股份目標價22港元,買入評級。野村則上調公司目標價至21.9港元,維持“買入”評級。並稱山東藥品集中採購對威高短期影響較少,長期而言,對其骨科業務持樂觀態度。惟大摩預期今年盈利增長將放緩,相信股價進一步上漲空間有限。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.